What are the indications, dosing regimen, contraindications, adverse effects, drug interactions, and monitoring recommendations for inclisiran (Leqvio)?

Inclisiran (Leqvio): Complete Clinical Information

Inclisiran is a small interfering RNA (siRNA) therapy that reduces LDL cholesterol by approximately 50% through twice-yearly subcutaneous injections, FDA-approved as adjunctive therapy to maximally tolerated statins in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering. 1

Mechanism of Action

Inclisiran is a long-acting synthetic siRNA that selectively silences PCSK9 messenger RNA translation by binding to the RNA-induced silencing complex, thereby inhibiting hepatic PCSK9 protein production at the intracellular level. This mechanism differs fundamentally from PCSK9 monoclonal antibodies (evolocumab, alirocumab), which bind extracellularly to already-produced PCSK9 protein. By reducing PCSK9 synthesis, inclisiran increases LDL receptor density on hepatocytes, enhancing LDL-C clearance from circulation. 1

FDA-Approved Indications

Inclisiran is indicated as adjunct to diet and maximally tolerated statin therapy for:

• Adults with heterozygous familial hypercholesterolemia (HeFH) requiring additional LDL-C lowering
• Adults with clinical ASCVD requiring additional LDL-C lowering

FDA approval was granted in December 2021. 1

Dosing Regimen

The recommended dosage is 284 mg administered as subcutaneous injection:

• Initial dose: Day 1
• Second dose: 3 months (Day 90)
• Maintenance: Every 6 months thereafter (Days 270,450,630, etc.)

Must be administered by a healthcare provider and billed under medical benefit rather than pharmacy benefit. 1

Pediatric Dosing

Recent evidence supports inclisiran sodium 300 mg subcutaneously in adolescents aged 12 to <18 years with HeFH, following the same dosing schedule (baseline, 3 months, then every 6 months). 2

Efficacy

LDL-C Reduction

In pooled analysis of 3,660 patients from ORION-9, ORION-10, and ORION-11 trials:

• Mean placebo-corrected LDL-C reduction at Day 510: 50.7% (95% CI: 52.9% to 48.4%; P<0.0001)
• Time-adjusted mean LDL-C reduction: 50.5% (95% CI: 52.1% to 48.9%; P<0.0001)

The LDL-C lowering response appears approximately 10% less than PCSK9 monoclonal antibodies when comparing similarly designed trials. 1

Additional Lipid Effects

• Lipoprotein(a) reduction: Approximately 18-33% 3, 4
• Total cholesterol reduction: Approximately 30% 3
• Triglyceride reduction: Approximately 35% 3

Adolescent Population

In ORION-16 trial (141 adolescents with HeFH):

• LDL-C reduction at Day 330: -27.1% vs +1.4% placebo (difference: -28.5%; 95% CI -35.8 to -21.3; P<0.0001)
• Sustained efficacy at Day 720: -33.7% mean reduction from baseline 2

Contraindications

No specific contraindications are listed in the available evidence. However, standard precautions for subcutaneous injections apply.

Adverse Effects

Common Adverse Effects

• Injection site reactions: 5.0% vs 0.7% placebo (predominantly mild, none severe or persistent) 1
• Upper respiratory tract infection
• Muscle spasms
• Hyperuricemia
• Back pain
• Abdominal pain or discomfort
• Bronchitis
• Pain in extremities
• Anemia
• Elevated liver enzymes
• Diarrhea
• Arthralgia 1

Safety Profile

Overall safety was similar to placebo in clinical trials. No treatment-related serious adverse events or deaths occurred in the ORION trials. In adolescents, injection site reactions occurred in 16% (all mild, none leading to discontinuation). 1, 2

Important Safety Considerations

• Hepatic impairment: Inclisiran exposure increased 1.24-fold in mild hepatic impairment and 2.03-fold in moderate hepatic impairment, but pharmacodynamic effects remained relatively unchanged. No dose adjustment needed, though long-term safety requires further evaluation. 5
• Pregnancy/Lactation: Discontinue when pregnancy is recognized unless benefits outweigh risks. No available data on use in pregnant women. 1

Drug Interactions

Specific drug interactions are not extensively documented in the available evidence. Unlike bempedoic acid, which requires avoiding concomitant simvastatin >20 mg or pravastatin >40 mg daily, inclisiran does not appear to have similar restrictions. 1

Monitoring Recommendations

Monitor the following parameters:

• LDL-C levels: Assess response to therapy at appropriate intervals (typically 3-6 months after initiation)
• Adherence to lifestyle modifications and statin therapy
• Injection site reactions: Assess at each administration
• Liver enzymes: If clinically indicated
• Lipid panel: Including total cholesterol, triglycerides, and consider Lp(a) monitoring

Regular blood samples or visits after starting medication to monitor adherence and potential adverse effects are encouraged. 6

Clinical Positioning

When to Consider Inclisiran

PCSK9 monoclonal antibodies remain preferred as initial PCSK9 inhibitor therapy due to demonstrated cardiovascular outcomes benefits in FOURIER and ODYSSEY Outcomes trials. 1

Inclisiran may be considered in specific scenarios:

• Patients with demonstrated poor adherence to PCSK9 mAbs (twice-yearly dosing advantage)
• Patients experiencing adverse effects from both PCSK9 mAbs
• Patients unable to self-inject
• Patients preferring less frequent dosing despite higher initial-year costs 1

Treatment Algorithm Position

According to 2022 ACC Expert Consensus:

1. First-line nonstatin: Ezetimibe
2. Second-line: PCSK9 mAb (preferred) or inclisiran (in specific circumstances)
3. Third-line: Bempedoic acid (especially with statin intolerance)

Do not combine PCSK9 mAb with inclisiran - no evidence for additional efficacy or cardiovascular benefit. If inclisiran is used, it should replace (not supplement) a PCSK9 mAb. 1

Cardiovascular Outcomes Data

Critical limitation: The effect of inclisiran on cardiovascular morbidity and mortality has not yet been determined. 1

Ongoing Outcomes Trials

• ORION-4: ~15,000 participants, completion expected 2026; primary endpoint includes coronary heart disease death, nonfatal MI, fatal/nonfatal ischemic stroke, urgent coronary revascularization 1
• VICTORION-2P: ~15,000 participants, completion expected 2027; primary endpoint includes CV death, nonfatal MI, nonfatal ischemic stroke 1

Until these trials are completed, cardiovascular benefits remain presumed based on LDL-C lowering rather than proven.

Cost and Access Considerations

Important practical barriers:

• Must be administered by clinician (cannot self-inject)
• Billed under medical benefit, not pharmacy benefit
• Initial year cost higher than PCSK9 mAbs; subsequent years more comparable
• Patient assistance programs and copay support available for eligible patients
• Requires prior authorization 1

Key Clinical Pearls

• Dosing advantage: Twice-yearly administration after initial loading (vs. every 2-4 weeks for PCSK9 mAbs) is the primary clinical advantage
• Efficacy trade-off: Approximately 10% less LDL-C reduction compared to PCSK9 mAbs
• No neutralizing antibodies: Unlike PCSK9 mAbs, inclisiran has not been noted to induce neutralizing antidrug antibodies
• Referral threshold: If patient fails to achieve <50% LDL-C reduction or LDL-C <70 mg/dL on maximally tolerated statin ± ezetimibe ± bempedoic acid, and inclisiran is being considered, refer to lipid specialist 1